Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade : evidence of improved immune regulation. / Ablamunits, Vitaly; Henegariu, Octavian; Hansen, Jakob Bondo; Opare-Addo, Lynn; Preston-Hurlburt, Paula; Santamaria, Pere; Mandrup-Poulsen, Thomas; Herold, Kevan C.
In: Diabetes, Vol. 61, No. 1, 2012, p. 145-54.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade
T2 - evidence of improved immune regulation
AU - Ablamunits, Vitaly
AU - Henegariu, Octavian
AU - Hansen, Jakob Bondo
AU - Opare-Addo, Lynn
AU - Preston-Hurlburt, Paula
AU - Santamaria, Pere
AU - Mandrup-Poulsen, Thomas
AU - Herold, Kevan C
PY - 2012
Y1 - 2012
N2 - Inflammatory cytokines are involved in autoimmune diabetes: among the most prominent is interleukin (IL)-1ß. We postulated that blockade of IL-1ß would modulate the effects of anti-CD3 monoclonal antibody (mAb) in treating diabetes in NOD mice. To test this, we treated hyperglycemic NOD mice with F(ab')(2) fragments of anti-CD3 mAb with or without IL-1 receptor antagonist (IL-1RA), or anti-IL-1ß mAb. We studied the reversal of diabetes and effects of treatment on the immune system. Mice that received a combination of anti-CD3 mAb with IL-1RA showed a more rapid rate of remission of diabetes than mice treated with anti-CD3 mAb or IL-1RA alone. Combination-treated mice had increased IL-5, IL-4, and interferon (IFN)-¿ levels in circulation. There were reduced pathogenic NOD-relevant V7 peptide-V7(+) T cells in the pancreatic lymph nodes. Their splenocytes secreted more IL-10, had increased arginase expression in macrophages and dendritic cells, and had delayed adoptive transfer of diabetes. After 1 month, there were increased concentrations of IgG1 isotype antibodies and reduced intrapancreatic expression of IFN-¿, IL-6, and IL-17 despite normal splenocyte cytokine secretion. These studies indicate that the combination of anti-CD3 mAb with IL-1RA is synergistic in reversal of diabetes through a combination of mechanisms. The combination causes persistent remission from islet inflammation.
AB - Inflammatory cytokines are involved in autoimmune diabetes: among the most prominent is interleukin (IL)-1ß. We postulated that blockade of IL-1ß would modulate the effects of anti-CD3 monoclonal antibody (mAb) in treating diabetes in NOD mice. To test this, we treated hyperglycemic NOD mice with F(ab')(2) fragments of anti-CD3 mAb with or without IL-1 receptor antagonist (IL-1RA), or anti-IL-1ß mAb. We studied the reversal of diabetes and effects of treatment on the immune system. Mice that received a combination of anti-CD3 mAb with IL-1RA showed a more rapid rate of remission of diabetes than mice treated with anti-CD3 mAb or IL-1RA alone. Combination-treated mice had increased IL-5, IL-4, and interferon (IFN)-¿ levels in circulation. There were reduced pathogenic NOD-relevant V7 peptide-V7(+) T cells in the pancreatic lymph nodes. Their splenocytes secreted more IL-10, had increased arginase expression in macrophages and dendritic cells, and had delayed adoptive transfer of diabetes. After 1 month, there were increased concentrations of IgG1 isotype antibodies and reduced intrapancreatic expression of IFN-¿, IL-6, and IL-17 despite normal splenocyte cytokine secretion. These studies indicate that the combination of anti-CD3 mAb with IL-1RA is synergistic in reversal of diabetes through a combination of mechanisms. The combination causes persistent remission from islet inflammation.
KW - Animals
KW - Antibodies, Monoclonal
KW - Antigens, CD3
KW - Diabetes Mellitus, Type 1
KW - Drug Combinations
KW - Drug Synergism
KW - Female
KW - Immune System Processes
KW - Immunotherapy
KW - Interleukin 1 Receptor Antagonist Protein
KW - Interleukin-1
KW - Mice
KW - Mice, Inbred NOD
KW - Mice, SCID
KW - Remission Induction
U2 - 10.2337/db11-1033
DO - 10.2337/db11-1033
M3 - Journal article
C2 - 22043003
VL - 61
SP - 145
EP - 154
JO - Diabetes
JF - Diabetes
SN - 0012-1797
IS - 1
ER -
ID: 38412243